Telehealth RFPs Shift to Unit Economics and Integration After Teladoc's $65M Deal

Procurement criteria tighten around outcomes and unit economics

Recent investment research from HOLD.co and a 2026 buyer's guide from Bridge Global have reset how enterprise buyers will evaluate telehealth platforms over the next 12–18 months. The shift is away from pandemic-era "any access" metrics and toward durable clinical impact, workflow integration, and acquisition-cost efficiency. For benefits teams and population health leaders, this means reallocating budget from broad-scope vendors to platforms with documented line-of-business depth.

The HOLD.co report reframes telehealth as a durable delivery channel where platforms must now demonstrate quantified outcome or cost improvements in specific lines—behavioral health, cardiometabolic, musculoskeletal. Platforms that cannot show measurable clinical impact (such as documented PHQ-9 improvement in behavioral health or avoided inpatient admissions) will lose budget to vendors that can. The report explicitly lays out "right to win" criteria: measurable clinical or cost impact, workflow integration with payer and employer systems, and unit economics that work under tighter reimbursement.

Teladoc's $65M Catapult acquisition sets a new valuation benchmark

Teladoc acquired Catapult Health on February 5, 2025, for $65 million plus up to $5 million in earn-outs. Catapult generated roughly $30 million in trailing twelve-month revenue as of Q3 2024, putting the deal at approximately 2.17x revenue (up to 2.33x with earn-outs). This is a concrete benchmark for valuing integrated telehealth plus at-home diagnostics platforms and reflects materially tighter pricing discipline than 2020–2021 digital health deals.

For procurement teams, the multiple matters. Teladoc is paying roughly $65–70 million for $30 million in revenue to add at-home screening capability. This suggests integrated diagnostics and telehealth is priced as an add-on capability, not a standalone high-multiple platform. Enterprise buyers negotiating multi-product bundles can use this as leverage. If a vendor is pitching remote diagnostics or at-home labs as a premium-priced standalone, the Teladoc-Catapult benchmark provides a counter.

The acquisition also sharpens competitive dynamics. Teladoc now competes more directly with Amwell, Included Health, and Accolade on integrated virtual care plus navigation models. Point solutions in remote diagnostics (such as Omada or Livongo-style chronic platforms) now face a unified workflow competitor.

Build-versus-buy math becomes more explicit

Bridge Global's 2026 telehealth platform development guide provides structured cost ranges and feature checklists for enterprises considering custom builds rather than off-the-shelf platforms. The guide breaks down implementation cost drivers by module complexity, integration count, and regulatory scope, giving CIOs and CFOs a framework to estimate total cost of ownership for custom builds.

This affects capital versus operating budget decisions. Custom builds lean on capital expenditure and longer amortization but can reduce per-visit or vendor fees in high-volume environments. SaaS telehealth platforms remain opex-heavy with per-member-per-month or per-visit pricing but carry lower upfront costs. The guide positions in-house or near-from-scratch implementations with development partners against turnkey enterprise platforms from Teladoc, Amwell, MDLive, Doximity, and Zoom for Healthcare.

The guide also elevates vendor lock-in and data portability as explicit procurement risks. It encourages enterprises to treat proprietary telehealth platforms as a vendor lock-in risk if APIs and data portability are weak, and custom development partners as a delivery-risk vector for timeline, security, and regulatory missteps. As a result, expect RFPs to demand stronger API contracts and data ownership clauses from SaaS vendors.

What to watch

Risk committees will increasingly require proof of outcomes and cost per engaged member before greenlighting large telehealth expansions. Benefits and population health teams should reallocate budget away from generic, broad-scope telehealth vendors toward vendors with line-of-business depth and documented outcome data. Procurement teams negotiating multi-product bundles now have a concrete valuation benchmark in the Teladoc-Catapult deal. Use it. Finally, enterprises evaluating build versus buy should map the number of EHR and practice management integrations, required regulatory frameworks (HIPAA, HITRUST, GDPR, local data residency), and depth of remote monitoring and analytics to estimate total cost of ownership and compare against SaaS alternatives.